The rapidly advancing field of cancer therapeutics has led to increased longevity among cancer patients as well as increasing complexity of cancer-related illness and associated comorbid conditions. As a result, institutions and organizations that specialize in the in-patient care of cancer patients have similarly evolved to meet the constantly changing needs of this unique patient population. Within these institutions, the intensive care units that specialize in the care of critically ill cancer patients represent an especially unique clinical resource. This article explores some of the defining and distinguishing characteristics associated with oncology ICUs.
SiegelRLGiaquintoANJemalA. Cancer statistics, 2024. CA Cancer J Clin. 2024 Jan-Feb;74(1):12-49. doi: https://doi.org/10.3322/caac.21820. Epub 2024 Jan 17. Erratum in: CA Cancer J Clin. 2024 Mar-Apr;74(2):203. PMID: 38230766.
2.
World Health Organization. WHO Report on Cancer: Setting Priorities, Investing Wisely and Providing Care for All. World Health Organization; 2020.
3.
BrennerH. Long-term survival rates of cancer patients achieved by the end of the 20th century: A period analysis. Lancet. 2002;360(9340):1131-1135.
4.
SoaresMBozzaFAAzevedoLC, et al.Effects of organizational characteristics on outcomes and resource use in patients with cancer admitted to intensive care units. J Clin Oncol. 2016 Sep 20;34(27):3315-3324. doi: https://doi.org/10.1200/JCO.2016.66.9549. Epub 2016 Jul 18. PMID: 27432921.
HalpernNAGoldmanDATanKSPastoresSM. Trends in critical care beds and use among population groups and medicare and medicaid beneficiaries in the United States: 2000–2010. Crit Care Med. 2016;44(8):1490-1499.
8.
RosolemMMRabelloLSLisboaT,et al.Critically ill patients with cancer and sepsis: Clinical course and prognostic factors. J Crit Care. 2012 Jun;27(3):301-307. doi: https://doi.org/10.1016/j.jcrc.2011.06.014. Epub 2011 Aug 19. PMID: 21855281.
9.
WallaceSKRathiNKWallerDK, et al.Two decades of ICU utilization and hospital outcomes in a comprehensive cancer center. Crit Care Med. 2016;44(5):926-933.
10.
Gonçalves-PereiraJOliveiraAVieiraT, et al.Critically ill patient mortality by age: Long-term follow-up (CIMbA-LT). Ann Intensive Care. 2023;13(7). https://doi.org/10.1186/s13613-023-01102-3
11.
HorsterSStemmlerHJMandelPC, et al.Mortality of patients with hematological malignancy after admission to the intensive care unit. Onkologie. 2012;35(10):556-561.
12.
AsdahlPHChristensenSKjærsgaardA, et al.One-year mortality among non-surgical patients with hematological malignancies admitted to the intensive care unit: A Danish nationwide population-based cohort study. Intensive Care Med. 2020;46:756-765. https://doi.org/10.1007/s00134-019-05918-1
13.
PuxtyKMcLoonePQuasimT, et al.Survival in solid cancer patients following intensive care unit admission. Intensive Care Med. 2014;40:1409-1428. https://doi.org/10.1007/s00134-014-3471-9
14.
CorrêaLCTelesDSilvaOBDTrindade-FilhoGHLoureiroPCavalcatiMDSM. Predictors of mortality among patients with acute leukemias admitted to an intensive care unit specialized in patients with hematological disease at a Brazilian hospital. Hematol Transfus Cell Ther. 2020 Jan-Mar;42(1):33-39. doi: https://doi.org/10.1016/j.htct.2019.01.004. Epub 2019 Apr 26. PMID: 31103671; PMCID: PMC7031107.
15.
VincentFSoaresMMokartD, et al.In-hospital and day-120 survival of critically ill solid cancer patients after discharge of the intensive care units: results of a retrospective multicenter study—A Groupe de recherche respiratoire en réanimation en Onco–Hématologie (Grrr-OH) study. Ann Intensive Care. 2018;8(40). https://doi.org/10.1186/s13613-018-0386-6
KamatSChawlaSRajendramPPastoresSMKosteleckyNHalpernNA. An analysis of patients transferred to a tertiary oncological intensive care unit for defined procedures. Am J Crit Care. 2015 May;24(3):241-247. doi: https://doi.org/10.4037/ajcc2015174. PMID: 25934721.
19.
GutierrezCCárdenasYRBratcherK, et al.Out-of-hospital ICU transfers to an oncological referral center: Characteristics, resource utilization, and patient outcomes. J Intensive Care Med. 2019 Jan;34(1):55-61. doi: https://doi.org/10.1177/0885066616686536. Epub 2016 Dec 29. PMID: 28030995.
20.
SabirLRamlakhanSGoodacreS. Comparison of qSOFA and hospital early warning scores for prognosis in suspected sepsis in emergency department patients: A systematic review. Emerg Med J. 2022 Apr;39(4):284-294. doi: https://doi.org/10.1136/emermed-2020-210416. Epub 2021 Aug 17. PMID: 34404680.
21.
von Lilienfeld-ToalMMidgleyKLieberbachS,et al.Observation-based early warning scores to detect impending critical illness predict in-hospital and overall survival in patients undergoing allogeneic stem cell transplantation. Biol Blood Marrow Transplant. 2007 May;13(5):568-576. doi: https://doi.org/10.1016/j.bbmt.2006.12.455. PMID: 17448916.
22.
LindMLPhippsAIMooneyS,et al.Predictive value of 3 clinical criteria for sepsis (quick sequential organ failure assessment, systemic inflammatory response syndrome, and national early warning score) with respect to short-term mortality in allogeneic hematopoietic cell transplant recipients with suspected infections. Clin Infect Dis. 2021 Apr 8;72(7):1220-1229. doi: https://doi.org/10.1093/cid/ciaa214. PMID: 32133490; PMCID: PMC8028104.
23.
CooksleyTKitlowskiEHaji-MichaelP. Effectiveness of modified early warning score in predicting outcomes in oncology patients. QJM. 2012 Nov;105(11):1083-1088. doi: https://doi.org/10.1093/qjmed/hcs138. Epub 2012 Aug 1. PMID: 22855285.
24.
LeeJRJungYKKimHJ,et al.Derivation and validation of modified early warning score plus SpO2/FiO2 score for predicting acute deterioration of patients with hematological malignancies. Korean J Intern Med. 2020 Nov;35(6):1477-1488. doi: https://doi.org/10.3904/kjim.2018.438. Epub 2020 Mar 3. PMID: 32114753; PMCID: PMC7652654.
25.
AygunHEraybarSOzdemirFArmaganE. Predictive value of modified early warning scoring system for identifying critical patients with malignancy in emergency department. Arch Iran Med. 2020 Aug 1;23(8):536-541. doi: https://doi.org/10.34172/aim.2020.56. PMID: 32894965.
26.
YoungRSGobelBHSchumacherMLeeJWeaverCWeitzmanS. Use of the modified early warning score and serum lactate to prevent cardiopulmonary arrest in hematology-oncology patients: A quality improvement study. Am J Med Qual. 2014 Nov-Dec;29(6):530-537. doi: https://doi.org/10.1177/1062860613508305. Epub 2013 Nov 7. PMID: 24202295.
27.
MuralitharanSNelsonWDiS,et al.Machine learning-based early warning systems for clinical deterioration: Systematic scoping review. J Med Internet Res. 2021 Feb 4;23(2):e25187. doi: https://doi.org/10.2196/25187. PMID: 33538696; PMCID: PMC7892287.
28.
Tim Cooksley and others. Effectiveness of modified early warning score in predicting outcomes in oncology patients. QJM: An International Journal of Medicine. November 2012;105(11):1083-1088. https://doi.org/10.1093/qjmed/hcs138
29.
NagarajahSKrzyzanowskaMKMurphyT. Early warning scores and their application in the inpatient oncology settings. JCO Oncol Pract. 2022 Jun;18(6):465-473. doi: https://doi.org/10.1200/OP.21.00532. Epub 2022 Jan 7. PMID: 34995083.
30.
HuSBWongDJCorreaALiNDengJC. Prediction of clinical deterioration in hospitalized adult patients with hematologic malignancies using a neural network model. PLoS One. 2016 Aug 17;11(8):e0161401. doi: https://doi.org/10.1371/journal.pone.0161401. PMID: 27532679; PMCID: PMC4988721.
31.
AustinCAHanzakerCStaffordR,et al.Utilization of rapid response resources and outcomes in a comprehensive cancer center*. Crit Care Med. 2014 Apr;42(4):905-909. doi: https://doi.org/10.1097/CCM.0000000000000098. PMID: 24361969; PMCID: PMC7887929.
32.
GershkovichBFernandoSMHerrittB, et al.Outcomes of hospitalized hematologic oncology patients receiving rapid response system activation for acute deterioration. Crit Care. 2019 Aug 27;23(1):286. doi: https://doi.org/10.1186/s13054-019-2568-5. PMID: 31455376; PMCID: PMC6712869.
33.
TaheriLAnandanadesanRde LavalladeH,et al.The role of a critical care outreach service in the management of patients with haematological malignancy. J Intensive Care Soc. 2019 Nov;20(4):327-334. doi: https://doi.org/10.1177/1751143719855201. Epub 2019 Jun 10. PMID: 31695737; PMCID: PMC6820225.
34.
AzoulayEMokartDPèneF, et al.Outcomes of critically ill patients with hematologic malignancies: Prospective multicenter data from France and Belgium—a groupe de recherche respiratoire en réanimation onco-hématologique study. J Clin Oncol. 2013 Aug 1;31(22):2810-2818. doi: https://doi.org/10.1200/JCO.2012.47.2365. Epub 2013 Jun 10. PMID: 23752112.
35.
LenglinéERaffouxELemialeV, et al.Intensive care unit management of patients with newly diagnosed acute myeloid leukemia with no organ failure. Leuk Lymphoma. 2012 Jul;53(7):1352-1359. doi: https://doi.org/10.3109/10428194.2011.649752. Epub 2012 Feb 13. PMID: 22233111.
36.
BuchholzTBarzolaMTaybanYHalpernNA. A rapid response team (RRT) system at a cancer center: Innovative approaches to system organization and clinical RRT pathways. Crit Care Nurs Q. April/June 2023;46(2):116-125. DOI: https://doi.org/10.1097/CNQ.0000000000000444
37.
Jones, Daryla; Moran, Julia; Winters, Bradfordb; Welch, Johnc,d. The rapid response system and end-of-life care. Curr Opin Crit Care. December 2013;19(6):616-623. DOI: https://doi.org/10.1097/MCC.0b013e3283636be2
38.
DownarJRodinDBaruaR,et al.Rapid response teams, do not resuscitate orders, and potential opportunities to improve end-of-life care: A multicentre retrospective study. J Crit Care. 2013 Aug;28(4):498-503. doi: https://doi.org/10.1016/j.jcrc.2012.10.002. Epub 2013 Jan 18. PMID: 23337483.
39.
LeapeLLCullenDJClappMD, et al.Pharmacist participation on physician rounds and adverse drug events in the intensive care unit. JAMA. 1999;282(3):267-270. doi:https://doi.org/10.1001/jama.282.3.267
40.
MacLarenRBondCAMartinSJFikeD. Clinical and economic outcomes of involving pharmacists in the direct care of critically ill patients with infections. Crit Care Med. December 2008;36(12):3184-3189. DOI: https://doi.org/10.1097/CCM.0b013e31818f2269
41.
LeeHRyuKSohnYKimJSuhGYKimE. Impact on patient outcomes of pharmacist participation in multidisciplinary critical care teams: A systematic review and meta-analysis. Crit Care Med. 2019 Sep;47(9):1243-1250. doi: https://doi.org/10.1097/CCM.0000000000003830. PMID: 31135496.
42.
AugustDAHuhmannMA.S.P.E.N. clinical guidelines: Nutrition support therapy during adult anticancer treatment and in hematopoietic cell transplantation. JPEN J Parenter Enteral Nutr. 2009;33(5):472-500.
43.
McClaveSATaylorBMartindaleR, et al.Guidelines for the provision and assessment of nutrition support therapy in the adult critically ill patient: Society of critical care medicine (SCCM) and American Society for Parenteral and Enteral Nutrition (A.S.P.E.N.). JPEN J Parenter Enteral Nutr. 2016;40(2):159-211.
44.
LachKPetersonSJ. Nutrition support for critically ill patients with cancer. Nutr Clin Pract. 2017;32(5):578-586.
45.
TuckerAMHallJMowatt-LarssenC. Supportive care considerations and nutrition support for critically ill cancer patients. In: NatesJLPriceKJ eds. ,Oncologic Critical Care. Springer International Publishing; 2018:1-18.
46.
ChristiansenCFJohansenMBLangebergWJFryzekJPSørensenHT. Incidence of acute kidney injury in cancer patients: A Danish population-based cohort study. Eur J Intern Med. 2011 Aug;22(4):399-406. doi: https://doi.org/10.1016/j.ejim.2011.05.005. Epub 2011 Jun 8. PMID: 21767759.
47.
BladéJFernández-LlamaPBoschF, et al.Renal failure in multiple myeloma: Presenting features and predictors of outcome in 94 patients from a single institution. Arch Intern Med. 1998;158(17):1889-1893. doi:https://doi.org/10.1001/archinte.158.17.1889
48.
SalahudeenAKDoshiSMPawarTNowshadGLahotiAShahP. Incidence rate, clinical correlates, and outcomes of AKI in patients admitted to a comprehensive cancer center. Clin J Am Soc Nephrol. March 2013;8(3):347-354. DOI: https://doi.org/10.2215/CJN.03530412
49.
BenoitDDHosteEA. Acute kidney injury in critically ill patients with cancer. Crit Care Clin. 2010 Jan;26(1):151-179. doi: https://doi.org/10.1016/j.ccc.2009.09.002. PMID: 19944280.
50.
AbudayyehASongJAbdelrahimM, et al.Renal replacement therapy in patients with stage IV cancer admitted to the intensive care unit with acute kidney injury at a comprehensive cancer center was not associated with survival. Am J Hosp Palliat Care. 2020 Sep;37(9):707-715. doi: https://doi.org/10.1177/1049909120902115. Epub 2020 Jan 27. PMID: 31986903; PMCID: PMC7363512.
51.
DarmonMVincentFCanetE, et al.Acute kidney injury in critically ill patients with haematological malignancies: Results of a multicentre cohort study from the Groupe de Recherche en Réanimation Respiratoire en Onco-Hématologie. Nephrol Dial Transplant. 2015 Dec;30(12):2006-2013. doi: https://doi.org/10.1093/ndt/gfv372. PMID: 26597921; PMCID: PMC4832999.
52.
ZhaoYIbrahimHBaileyJA, et al.Therapeutic plasma exchange performed in tandem with hemodialysis without supplemental calcium in the apheresis circuit. J Clin Apher. 2017 Jun;32(3):154-157. doi: https://doi.org/10.1002/jca.21473. Epub 2016 May 13. PMID: 27172986.
53.
SchaeferBUjszasziASchaeferSHeckertKHSchaeferFSchmittCP. Safety and efficacy of tandem hemodialysis and plasma exchange in children. Clin J Am Soc Nephrol. 2014 Sep 5;9(9):1563-1570. doi: https://doi.org/10.2215/CJN.12581213. Epub 2014 Jul 3. PMID: 24993449; PMCID: PMC4152820.
54.
ZhangDZhuYJinYKawemeNMDongY. Leukapheresis and hyperleukocytosis, past and future. Int J Gen Med. 2021 Jul 14;14:3457-3467. doi: https://doi.org/10.2147/IJGM.S321787. PMID: 34285568; PMCID: PMC8286901.
55.
McKeeLCJrCollinsRD. Intravascular leukocyte thrombi and aggregates as a cause of morbidity and mortality in leukemia. Medicine (Baltimore). 1974 Nov;53(6):463-478. doi: https://doi.org/10.1097/00005792-197411000-00006. PMID: 4530890.
56.
AliAMMirrakhimovAEAbboudCNCashenAF. Leukostasis in adult acute hyperleukocytic leukemia: A clinician's digest. Hematol Oncol. 2016 Jun;34(2):69-78. doi: https://doi.org/10.1002/hon.2292. Epub 2016 Mar 27. PMID: 27018197.
57.
PadmanabhanAConnelly-SmithLAquiN, et al.Guidelines on the use of therapeutic apheresis in clinical practice—evidence-based approach from the writing committee of the American Society for Apheresis: The eighth special issue. J Clin Apher. 2019 Jun;34(3):171-354. doi: https://doi.org/10.1002/jca.21705. PMID: 31180581.
58.
NguyenTCKissJEGoldmanJRCarcilloJA. The role of plasmapheresis in critical illness. Crit Care Clin. 2012 Jul;28(3):453-68, vii. doi: https://doi.org/10.1016/j.ccc.2012.04.009. PMID: 22713617; PMCID: PMC3381605.
59.
HuYYangHFuSWuJ. Therapeutic plasma exchange: For cancer patients. Cancer Manag Res. 2022 Feb 2;14:411-425. doi: https://doi.org/10.2147/CMAR.S340472. PMID: 35140519; PMCID: PMC8818550.
60.
MerliniGBaldiniLBrogliaC, et al.Prognostic factors in symptomatic Waldenstrom's macroglobulinemia. Semin Oncol. 2003 Apr;30(2):211-215. doi: https://doi.org/10.1053/sonc.2003.50064. PMID: 12720138.
61.
LucchiMRicciardiRMelfiF,et al.Association of thymoma and myasthenia gravis: Oncological and neurological results of the surgical treatment. Eur J Cardiothorac Surg. 2009 May;35(5):812-816. discussion 816. doi: https://doi.org/10.1016/j.ejcts.2009.01.014. Epub 2009 Feb 23. PMID: 19237289.
62.
AzoulayELemialeVMokartD, et al.Acute respiratory distress syndrome in patients with malignancies. Intensive Care Med. 2014 Aug;40(8):1106-1114. doi: https://doi.org/10.1007/s00134-014-3354-0. Epub 2014 Jun 5. PMID: 24898895.
63.
GowKWLaoOBLeongTFortenberryJD. Extracorporeal life support for adults with malignancy and respiratory or cardiac failure: The extracorporeal life support experience. Am J Surg. 2010 May;199(5):669-675. doi: https://doi.org/10.1016/j.amjsurg.2010.01.018. PMID: 20466114.
64.
SchmidtMSchellongowskiPPatronitiN, et al.IDEA Study Group collaborators are as follows. Six-Month outcome of immunocompromised patients with severe acute respiratory distress syndrome rescued by extracorporeal membrane oxygenation. An international multicenter retrospective study. Am J Respir Crit Care Med. 2018 May 15;197(10):1297-1307. doi: https://doi.org/10.1164/rccm.201708-1761OC. PMID: 29298095; PMCID: PMC7252852.
65.
HeitJAO'FallonWMPettersonTMLohseCMSilversteinMDMohrDN. Melton LJ 3rd. Relative impact of risk factors for deep vein thrombosis and pulmonary embolism: A population-based study. Arch Intern Med. 2002 Jun 10;162(11):1245-1248. doi: https://doi.org/10.1001/archinte.162.11.1245. PMID: 12038942.
66.
SpencerFALessardDEmeryCReedGGoldbergRJ. Venous thromboembolism in the outpatient setting. Arch Intern Med. 2007 Jul 23;167(14):1471-1475. doi: https://doi.org/10.1001/archinte.167.14.1471. PMID: 17646600; PMCID: PMC2762787.
67.
BlomJWDoggenCJMOsantoSRosendaalFR. Malignancies, prothrombotic mutations, and the risk of venous thrombosis. JAMA. 2005;293(6):715-722. doi:https://doi.org/10.1001/jama.293.6.715
68.
HorstedFWestJGraingeMJ. Risk of venous thromboembolism in patients with cancer: A systematic review and meta-analysis. PLoS Med. 2012;9(7):e1001275. doi: https://doi.org/10.1371/journal.pmed.1001275. Epub 2012 Jul 31. PMID: 22859911; PMCID: PMC3409130.
69.
Cronin-FentonDPSøndergaardFPedersenLA,et al.Hospitalisation for venous thromboembolism in cancer patients and the general population: A population-based cohort study in Denmark, 1997-2006. Br J Cancer. 2010 Sep 28;103(7):947-953. doi: https://doi.org/10.1038/sj.bjc.6605883. Epub 2010 Sep 14. PMID: 20842120; PMCID: PMC2965880.
70.
AdelborgKCorrainiPDarvalicsB, et al.Risk of thromboembolic and bleeding outcomes following hematological cancers: A Danish population-based cohort study. J Thromb Haemost. 2019 Aug;17(8):1305-1318. doi: https://doi.org/10.1111/jth.14475. Epub 2019 Jun 5. PMID: 31054195.
71.
StreiffMBHolmstromBAngeliniD, et al.Cancer-associated venous thromboembolic disease, version 2.2021, NCCN clinical practice guidelines in oncology. J Natl Compr Canc Netw. 2021 Oct 15;19(10):1181-1201. doi: https://doi.org/10.6004/jnccn.2021.0047. PMID: 34666313.
72.
JollyBTMassarinEPigmanEC. Color Doppler ultrasonography by emergency physicians for the diagnosis of acute deep venous thrombosis. Acad Emerg Med. 1997 Feb;4(2):129-132. doi: https://doi.org/10.1111/j.1553-2712.1997.tb03719.x. PMID: 9043540.
73.
MagazziniSVanniSToccafondiS, et al.Duplex ultrasound in the emergency department for the diagnostic management of clinically suspected deep vein thrombosis. Acad Emerg Med. 2007 Mar;14(3):216-220. doi: https://doi.org/10.1197/j.aem.2006.08.023. Epub 2007 Jan 30. PMID: 17264203.
74.
KoryPDPellecchiaCMShilohALMayoPHDiBelloCKoenigS. Accuracy of ultrasonography performed by critical care physicians for the diagnosis of DVT. Chest. 2011 Mar;139(3):538-542. doi: https://doi.org/10.1378/chest.10-1479. Epub 2010 Oct 28. PMID: 21030490.
75.
Pedraza GarcíaJValle AlonsoJCeballos GarcíaPRico RodríguezFLópez MÁAMuñoz-VillanuevaMDC. Comparison of the accuracy of emergency department-performed point-of-care-ultrasound (POCUS) in the diagnosis of lower-extremity deep vein thrombosis. J Emerg Med. 2018 May;54(5):656-664. doi: https://doi.org/10.1016/j.jemermed.2017.12.020. Epub 2018 Jan 3. PMID: 29306580.
76.
LeeJHLeeSHYunSJ. Comparison of 2-point and 3-point point-of-care ultrasound techniques for deep vein thrombosis at the emergency department: A meta-analysis. Medicine (Baltimore). 2019 May;98(22):e15791. doi: https://doi.org/10.1097/MD.0000000000015791. PMID: 31145304; PMCID: PMC6709014.
77.
WangTYOuFSRoeMT,et al.Incidence and prognostic significance of thrombocytopenia developed during acute coronary syndrome in contemporary clinical practice. Circulation. 2009 May 12;119(18):2454-2462. doi: https://doi.org/10.1161/CIRCULATIONAHA.108.827162. Epub 2009 Apr 27. PMID: 19398666.
78.
BruckelJTWongSLChanPSBradleySMNallamothuBK. Patterns of resuscitation care and survival after in-hospital cardiac arrest in patients with advanced cancer. J Oncol Pract. 2017 Oct;13(10):e821-e830. doi: https://doi.org/10.1200/JOP.2016.020404. Epub 2017 Aug 1. PMID: 28763260; PMCID: PMC5640412.
79.
GuhaABuckBBiersmithM, et al.Contemporary impacts of a cancer diagnosis on survival following in-hospital cardiac arrest. Resuscitation. 2019 Sep;142:30-37. doi: https://doi.org/10.1016/j.resuscitation.2019.07.005. Epub 2019 Jul 13. PMID: 31310845; PMCID: PMC7881763.
80.
ChawlaSGutierrezCRajendramP, et al.Indicators of clinical trajectory in patients with cancer who receive cardiopulmonary resuscitation. J Natl Compr Canc Netw. 2023 Jan;21(1):51-59.e10. doi: https://doi.org/10.6004/jnccn.2022.7072. PMID: 36634611; PMCID: PMC10228640.
JohanssonPIStensballeJ. Hemostatic resuscitation for massive bleeding: The paradigm of plasma and platelets—A review of the current literature. Transfusion. 2010 Mar;50(3):701-710. doi: https://doi.org/10.1111/j.1537-2995.2009.02458.x. Epub 2009 Nov 19. PMID: 19929864.
83.
MeyerDEVincentLEFoxEE,et al.Every minute counts: Time to delivery of initial massive transfusion cooler and its impact on mortality. J Trauma Acute Care Surg. 2017 Jul;83(1):19-24. doi: https://doi.org/10.1097/TA.0000000000001531. PMID: 28452870; PMCID: PMC5526458.
84.
BadamiKGNealCSparrowRL,et al.Red blood cell alloantibodies in the context of critical bleeding and massive transfusion. Blood Transfus. 2023 Sep;21(5):390-399. doi: https://doi.org/10.2450/2022.0131-22. Epub 2022 Oct 18. PMID: 36346883; PMCID: PMC10497381.
85.
El FetouhRMAElmoniemGMAAllamRMSobeihMEKamelMMRadwanSM. Frequency and specificity of red blood cell alloantibodies in multitransfused Egyptian patients with hematological and nonhematological malignancies. Transfus Apher Sci. 2020 Dec;59(6):102909. doi: https://doi.org/10.1016/j.transci.2020.102909. Epub 2020 Aug 22. PMID: 32888823.
86.
BergaminFSAlmeidaJPLandoniG, et al.Liberal versus restrictive transfusion strategy in critically ill oncologic patients: The transfusion requirements in critically ill oncologic patients randomized controlled trial. Crit Care Med. 2017 May;45(5):766-773. doi: https://doi.org/10.1097/CCM.0000000000002283. PMID: 28240687.
87.
BotdorfJLedetCRBrydgesNLovinariaDBrydgesG. Enhanced recovery after surgery (ERAS) in the oncologic patient. In: NatesJLPriceKJ, eds. Oncologic Critical Care. Springer International Publishing; 2019:1-32. doi:https://doi.org/10.1007/978-3-319-74698-2_202-1
88.
ThevathasanTCopelandCCLongDR, et al.The impact of postoperative intensive care unit admission on postoperative hospital length of stay and costs: A prespecified propensity-matched cohort study. Anesth Analg. 2019;129(3):753-761. doi:https://doi.org/10.1213/ANE.0000000000003946
89.
TacconePLangerTGrasselliG. Do we really need postoperative ICU management after elective surgery? No, not any more!. Intensive Care Med. 2017;43(7):1037-1038. doi:https://doi.org/10.1007/s00134-017-4814-0
90.
KahanBCKoulentiDArvanitiK, et al.Critical care admission following elective surgery was not associated with survival benefit: Prospective analysis of data from 27 countries. Intensive Care Med. 2017;43(7):971-979. doi:https://doi.org/10.1007/s00134-016-4633-8
91.
TanerCBWillinghamDLBulataoIG, et al.Is a mandatory intensive care unit stay needed after liver transplantation? Feasibility of fast-tracking to the surgical ward after liver transplantation. Liver Transpl. 2012;18(3):361-369. doi:https://doi.org/10.1002/lt.22459
92.
BertgesDJRheeRYMulukSC, et al.Is routine use of the intensive care unit after elective infrarenal abdominal aortic aneurysm repair necessary?J Vasc Surg. 2000;32(4):634-642. doi:https://doi.org/10.1067/mva.2000.110173
93.
SuttonTLPotterKCO’GradyJ, et al.Intensive care unit observation after pancreatectomy: Treating the patient or the surgeon?J Surg Oncol. 2022;125(5):847-855. doi:https://doi.org/10.1002/jso.26800
94.
CerulloMGaniFChenSY, et al.Routine intensive care unit admission among patients undergoing major pancreatic surgery for cancer: No effect on failure to rescue. Surgery. 2019;165(4):741-746. doi:https://doi.org/10.1016/j.surg.2018.11.005
95.
NkenkeEVairaktarisEStelzleFNeukamFWSt. PierreM. No reduction in complication rate by stay in the intensive care unit for patients undergoing surgery for head and neck cancer and microvascular reconstruction. Head Neck. 2009;31(11):1461-1469. doi:https://doi.org/10.1002/hed.21117
96.
ToEWHTsangWMLaiECHChuMC. Retrospective study on the need of intensive care unit admission after major head and neck surgery. ANZ J Surg. 2002;72(1):11-14. doi:https://doi.org/10.1046/j.1445-2197.2002.02285.x
DortJCFarwellDGFindlayM, et al.Optimal perioperative care in major head and neck cancer surgery with free flap reconstruction: A consensus review and recommendations from the enhanced recovery after surgery society. JAMA Otolaryngol Head Neck Surg. 2017;143(3):292. doi:https://doi.org/10.1001/jamaoto.2016.2981
GrecoMCaprettiGBerettaLGemmaMPecorelliNBragaM. Enhanced recovery program in colorectal surgery: A meta-analysis of randomized controlled trials. World J Surg. Published online2014;Jun;38(6):1531-41.
101.
VaradhanKK. The enhanced recovery after surgery (ERAS) pathway for patients undergoing major elective open colorectal surgery: A meta-analysis of randomized controlled trials. Clin Nutr. Published online2010;Aug;29(4):434-40.
102.
ERAS Compliance Group. The impact of enhanced recovery protocol compliance on elective colorectal cancer resection: Results from an international registry. Ann Surg. 2015;261(6):1153-1159. doi:https://doi.org/10.1097/SLA.0000000000001029
103.
BischSPJagoCAKalogeraE, et al.Outcomes of enhanced recovery after surgery (ERAS) in gynecologic oncology—A systematic review and meta-analysis. Gynecol Oncol. 2021;161(1):46-55. doi:https://doi.org/10.1016/j.ygyno.2020.12.035
104.
MelloulELassenKRoulinD, et al.Guidelines for perioperative care for pancreatoduodenectomy: Enhanced recovery after surgery (ERAS) recommendations 2019. World J Surg. 2020;44(7):2056-2084. doi:https://doi.org/10.1007/s00268-020-05462-w
105.
Temple-OberleCShea-BudgellMATanM, et al.Consensus review of optimal perioperative care in breast reconstruction: Enhanced recovery after surgery (ERAS) society recommendations. Plastic & Reconstructive Surgery. 2017;139(5):1056e-1071e. doi:https://doi.org/10.1097/PRS.0000000000003242
106.
NelsonGFotopoulouCTaylorJ, et al.Enhanced recovery after surgery (ERAS®) society guidelines for gynecologic oncology: Addressing implementation challenges—2023 update. Gynecol Oncol. 2023;173:58-67. doi:https://doi.org/10.1016/j.ygyno.2023.04.009
107.
AraosRAldanaG. Frequent central nervous system (CNS) infections in the immunosuppressed patient. In: NatesJLPriceKJ, eds. Oncologic Critical Care. Springer International Publishing; 2019:1-8.
108.
Schmidt-HieberMSilingGSchalkE, et al. CNS infections in patients with hematological disorders (including allogeneic stem-cell transplantation)—Guidelines of the Infectious Diseases Working Party (AGIHO) of the German Society of Hematology and Medical Oncology (DGHO). Ann Oncol. 2016;27(7):1207-1225.
109.
ToomeyDTHillJZerrD. Viral encephalitis after hematopoietic cell transplantation: A systematic review. Transplant Cell Ther. 2023;29(10):636 e1–636 e9.
110.
MajdNKLoghinME. Leptomeningeal disease in solid cancers. In: NatesJLPriceKJ, eds. Oncologic Critical Care. Springer International Publishing; 2019:1-19.
111.
ChamberlainMC. Comprehensive neuraxis imaging in leptomeningeal metastasis: A retrospective case series. CNS Oncol. 2013;2(2):121-128.
112.
LeeDWSantomassoBLockeF, et al.ASTCT consensus grading for cytokine release syndrome and neurologic toxicity associated with immune effector cells. Biol Blood Marrow Transplant. 2019;25(4):625-638.
113.
HuaGScanlanRStrainingR, et al.Teclistamab-cqyv: The first bispecific T-cell engager antibody for the treatment of patients with relapsed or refractory multiple myeloma. J Adv Pract Oncol. 2023;14(2):163-171.
CaiYShekPYTeoI,et al.A multidisciplinary antimicrobial stewardship programme safely decreases the duration of broad-spectrum antibiotic prescription in Singaporean adult renal patients. Int J Antimicrob Agents. 2016 Jan;47(1):91-96. doi: https://doi.org/10.1016/j.ijantimicag.2015.10.021. Epub 2015 Nov 26. PMID: 26706421.
118.
SeahVXFOngRYLLimASYChongCYTanNWHThoonKC. Impact of a carbapenem antimicrobial stewardship program on patient outcomes. Antimicrob Agents Chemother. 2017 Aug 24;61(9):e00736-17. doi: https://doi.org/10.1128/AAC.00736-17. PMID: 28717037; PMCID: PMC5571328.
119.
OwensRCJr. Antimicrobial stewardship: Concepts and strategies in the 21st century. Diagn Microbiol Infect Dis. 2008 May;61(1):110-128. doi: https://doi.org/10.1016/j.diagmicrobio.2008.02.012. Epub 2008 Apr 2. PMID: 18384997.
120.
RobilottiEHolubarMSeoSKDeresinskiS. Feasibility and applicability of antimicrobial stewardship in immunocompromised patients. Curr Opin Infect Dis. 2017;Aug;30(4):346-353..
121.
PillingerKEBouchardJWithersST, et al.Inpatient antibiotic stewardship interventions in the adult oncology and hematopoietic stem cell transplant population: A review of the literature. Ann Pharmacother. 2020;54(6):594-610. doi:https://doi.org/10.1177/1060028019890886
122.
Aguilar-GuisadoMEspigadoIMartín-PeñaA, et al.Optimisation of empirical antimicrobial therapy in patients with haematological malignancies and febrile neutropenia (how long study): An open-label, randomised, controlled phase 4 trial. Lancet Haematol. 2017 Dec;4(12):e573-e583. doi: https://doi.org/10.1016/S2352-3026(17)30211-9. Epub 2017 Nov 15. PMID: 29153975.
123.
SternACarraraEBittermanRYahavDLeiboviciLPaulM. Early discontinuation of antibiotics for febrile neutropenia versus continuation until neutropenia resolution in people with cancer. Cochrane Database Syst Rev. 2019;201.
124.
MihuCNRhombergPRJonesRNCoyleEPrinceRARolstonKV. Escherichia coli resistance to quinolones at a comprehensive cancer center. Diagn Microbiol Infect Dis. 2010 Jul;67(3):266-269. doi: https://doi.org/10.1016/j.diagmicrobio.2010.02.014. Epub 2010 May 15. PMID: 20471765.
125.
BhusalYMihuCNTarrandJJRolstonKV. Incidence of fluoroquinolone-resistant and extended-spectrum β-lactamase-producing Escherichia coli at a comprehensive cancer center in the United States. Chemotherapy. 2011;57(4):335-338. doi: https://doi.org/10.1159/000329661. Epub 2011 Sep 6. PMID: 21912115.
126.
KernWVKloseKJellen-RitterAS, et al.Fluoroquinolone resistance of Escherichia coli at a cancer center: Epidemiologic evolution and effects of discontinuing prophylactic fluoroquinolone use in neutropenic patients with leukemia. Eur J Clin Microbiol Infect Dis. 2005 Feb;24(2):111-118. doi: https://doi.org/10.1007/s10096-005-1278-x. PMID: 15714332.
127.
TrecarichiEMTumbarelloMSpanuT, et al.Incidence and clinical impact of extended-spectrum-beta-lactamase (ESBL) production and fluoroquinolone resistance in bloodstream infections caused by Escherichia coli in patients with hematological malignancies. J Infect. 2009;58(4):299-307.
128.
MontassierEBatardEGastinneTPotelGde La CochetièreMF. Recent changes in bacteremia in patients with cancer: A systematic review of epidemiology and antibiotic resistance. Eur J Clin Microbiol Infect Dis. 2013 Jul;32(7):841-850. doi: https://doi.org/10.1007/s10096-013-1819-7. Epub 2013 Jan 25. PMID: 23354675.
129.
WrightAAZhangBRayA, et al.Associations between end-of-life discussions, patient mental health, medical care near death, and caregiver bereavement adjustment. JAMA. 2008;300(14):1665-1673. doi:https://doi.org/10.1001/jama.300.14.1665
130.
WrightAAKeatingNLBalboniTAMatulonisUABlockSDPrigersonHG. Place of death: Correlations with quality of life of patients with cancer and predictors of bereaved caregivers’ mental health. J Clin Oncol. 2010 Oct 10;28(29):4457-4464. doi: https://doi.org/10.1200/JCO.2009.26.3863. Epub 2010 Sep 13. PMID: 20837950; PMCID: PMC2988637.
131.
CheungMCEarleCCRangrejJ, et al.Impact of aggressive management and palliative care on cancer costs in the final month of life. Cancer. 2015;121:3307-3315. https://doi.org/10.1002/cncr.29485
132.
Keim-MalpassJMitchellEMBlackhallLDeGuzmanPB. Evaluating stakeholder-identified barriers in accessing palliative care at an NCI-designated cancer center with a rural catchment area. J Palliat Med. 2015 Jul;18(7):634-637. doi: https://doi.org/10.1089/jpm.2015.0032. Epub 2015 Apr 21. PMID: 25897772.
133.
KumarPCasarettDCorcoranA,et al.Utilization of supportive and palliative care services among oncology outpatients at one academic cancer center: Determinants of use and barriers to access. J Palliat Med. 2012 Aug;15(8):923-930. doi: https://doi.org/10.1089/jpm.2011.0217. Epub 2012 Jun 25. PMID: 22731514; PMCID: PMC3396135.
134.
LeBlancTWO'DonnellJDCrowley-MatokaM, et al.Perceptions of palliative care among hematologic malignancy specialists: A mixed-methods study. J Oncol Pract. 2015 Mar;11(2):e230-e238. doi: https://doi.org/10.1200/JOP.2014.001859. PMID: 25784580; PMCID: PMC4893821.
135.
PatelMIPeriyakoilVSMooreDNevedalACokerTR. Delivering end-of-life cancer care: Perspectives of providers. Am J Hosp Palliat Care. 2018 Mar;35(3):497-504. doi: https://doi.org/10.1177/1049909117719879. Epub 2017 Jul 10. PMID: 28691498.
136.
OdejideOOSalas CoronadoDYWattsCDWrightAAAbelGA. End-of-life care for blood cancers: A series of focus groups with hematologic oncologists. J Oncol Pract. 2014 Nov;10(6):e396-e403. doi: https://doi.org/10.1200/JOP.2014.001537. Epub 2014 Oct 7. PMID: 25294393; PMCID: PMC5706135.
137.
WrightAAKeatingNLAyanianJZ, et al.Family perspectives on aggressive cancer care near the end of life. JAMA. 2016 Jan 19;315(3):284-292. doi: https://doi.org/10.1001/jama.2015.18604. PMID: 26784776; PMCID: PMC4919118.
138.
MackJWWeeksJCWrightAABlockSDPrigersonHG. End-of-life discussions, goal attainment, and distress at the end of life: Predictors and outcomes of receipt of care consistent with preferences. J Clin Oncol. 2010 Mar 1;28(7):1203-1208. doi: https://doi.org/10.1200/JCO.2009.25.4672. Epub 2010 Feb 1. PMID: 20124172; PMCID: PMC2834470.
139.
WeeksJCCatalanoPJCroninA,et al.Patients’ expectations about effects of chemotherapy for advanced cancer. N Engl J Med. 2012 Oct 25;367(17):1616-1625. doi: https://doi.org/10.1056/NEJMoa1204410. PMID: 23094723; PMCID: PMC3613151.
McNiffKKCaligiuriMADavidsonNE, et al.Improving goal concordant care among 10 leading academic U.S. Cancer hospitals: A collaboration of the alliance of dedicated cancer centers. The Oncol. 2021;26:533-536. https://doi.org/10.1002/onco.13850
142.
Fumić DunkićLHostićVKusturaA. Palliative treatment of intractable cancer pain. Acta Clin Croat. 2022 Sep;61(Suppl 2):109-114. doi: https://doi.org/10.20471/acc.2022.61.s2.14. PMID: 36824634; PMCID: PMC9942460.
143.
MercadanteS. Refractory cancer pain and intrathecal therapy: Critical review of a systematic review. Pain Ther. 2023 Jun;12(3):645-654. doi: https://doi.org/10.1007/s40122-023-00507-z. Epub 2023 Apr 13. PMID: 37055698; PMCID: PMC10199986.
144.
ChapmanACLinJACobertJ,et al.Utilization and delivery of specialty palliative care in the ICU: Insights from the palliative care quality network. J Pain Symptom Manage. 2022 Jun;63(6):e611-e619. doi: https://doi.org/10.1016/j.jpainsymman.2022.03.011. PMID: 35595374; PMCID: PMC9303815.
145.
ShahriariMGolshanAAlimohammadiNAbbasiSFazelK. Effects of pain management program on the length of stay of patients with decreased level of consciousness: A clinical trial. Iran J Nurs Midwifery Res. 2015 Jul-Aug;20(4):502-507. doi: https://doi.org/10.4103/1735-9066.160996. PMID: 26257808; PMCID: PMC4525351.
146.
KyeremantengKGagnonLPThavornKHeylandDD'EgidioG. The impact of palliative care consultation in the ICU on length of stay: A systematic review and cost evaluation. J Intensive Care Med. 2018 Jun;33(6):346-353. doi: https://doi.org/10.1177/0885066616664329. Epub 2016 Aug 31. PMID: 27582396.
147.
MaJChiSBuettnerB, et al.Early palliative care consultation in the medical ICU: A cluster randomized crossover trial. Crit Care Med. 2019 Dec;47(12):1707-1715. doi: https://doi.org/10.1097/CCM.0000000000004016. PMID: 31609772; PMCID: PMC6861688.
148.
BarataAAbramsHRMeyerC, et al.What do patients think about palliative care? A national survey of hematopoietic stem cell transplant recipients. Blood Adv. 2023 May 23;7(10):2032-2041. doi: https://doi.org/10.1182/bloodadvances.2023009712. PMID: 36877661; PMCID: PMC10188629.
